-
Human subjects training is typically a part of human subjects protections programs. Such training has taken the form of in-house seminars given at regular intervals and web-based activities. Regardless of the form, the objectives are simple: Give those involved in human subject research ethics and regulatory information that will promote beneficence and compliance with regulations.
-
-
In 1999, Chrissy Parker was a typical 14-year-old high school freshman riding home from school with a friend. Now, Parker is a college freshman whose name is frequently mentioned these days in the same sentence as Christopher Reeve.
-
Rehab usually isnt considered the most glamorous unit in the hospital. Emergency department, intensive care unit (ICU), obstetrics they get all the press. But the rehab unit at the University of Utah Hospital in Salt Lake City isnt going to take it anymore. Last year, they declared war on the rest of the hospital, and won hands down or hands clean, as the case may be.
-
During testimony late last year before the Department of Health and Human Services (HHS) National Committee on Vital and Health Statistics Subcommittee on Privacy and Confidentiality, Janlori Goldman, director of the Health Privacy Project (HPP) in Washington, DC, presented 13 myths that persist about the Health Insurance Portability and Accountability Acts (HIPAA) privacy regulation and facts addressing those myths.
-
Early detection and rapid treatment is one of the most effective strategies available to physicians for improving outcomes of patients with myocardial infarction. A variety of technologies are under development that are intended to improve the ability to detect a heart attack rapidly, while others are designed to help minimize the adverse consequences of an acute coronary event using novel modalities to support the heart or preserve heart tissue.
-
Presenters revealed some stunning data in coronary and peripheral revascularization during a press conference on late-breaking trials at the American College of Cardiologys (ACC; Bethesda, Maryland) annual scientific sessions in early March. The presentations at the Ernest N. Morial Convention Center included results from the three iterations of the ARCHeR (Acculink for Revascularization of Carotids in High-Risk Patients) trial, which is focused on treatment of carotid artery disease.
-
Arrow International (Reading, Pennsylvania) said last month that it plans to defer a U.S. clinical trial of its current iteration of the LionHeart Left Ventricular Assist System (LVAS) for a destination therapy indication, saying it prefers to see how the next generation of the device, which has a smaller battery and other system enhancements, fares in the European market, where it was approved via a CE mark last November.
-
Arrhythmia Research Technology (ART; Fitchburg, Massachusetts) said its wholly owned subsidiary, Micron Products, has completed the purchase of substantially all of the operating assets of privately held New England Molders (NEMI; Shrewsbury, Massachusetts).
-
Alliance Medical (Phoenix, Arizona), a reprocessor of single-use medical devices (SUDs), said VHA (Irving, Texas), a cooperative of community-owned healthcare organizations, has renewed a three-year contract with Alliance.
